{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:25:51Z","timestamp":1762100751153},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s11883-008-0011-5","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T14:03:18Z","timestamp":1201701798000},"page":"71-78","source":"Crossref","is-referenced-by-count":10,"title":["Rimonabant: New data and emerging experience"],"prefix":"10.1007","volume":"10","author":[{"given":"Suzanne M.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolien","family":"Dikkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","volume":"295","author":"C.L. Ogden","year":"2006","unstructured":"Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999\u20132004. JAMA 2006, 295:1549\u20131555.","journal-title":"JAMA"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/sj.ijo.0802421","volume":"28","author":"D. Jolliffe","year":"2004","unstructured":"Jolliffe D: Extent of overweight among US children and adolescents from 1971 to 2000. Int J Obes Relat Metab Disord 2004, 28:4\u20139.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ecl.2004.03.002","volume":"33","author":"G. Reaven","year":"2004","unstructured":"Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004, 33:283\u2013303.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jama.291.10.1238","volume":"291","author":"A.H. Mokdad","year":"2004","unstructured":"Mokdad AH, Marks JS, Stroup DF, Gerberding JL: Actual causes of death in the United States, 2000. JAMA 2004, 291:1238\u20131245.","journal-title":"JAMA"},{"key":"11_CR5","first-page":"1","volume":"3","author":"E. Beckley","year":"2006","unstructured":"Beckley E: New ADA initiative moved beyond \u201cmetabolic syndrome.\u201d Cardiometabolic risk proposed as umbrella term for diabetes risk factors. DOC News 2006, 3:1\u20133.","journal-title":"DOC News"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/agh110","volume":"40","author":"F. Rodriguez de Fonseca","year":"2005","unstructured":"Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, et al.: The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005, 40:2\u201314.","journal-title":"Alcohol Alcohol"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"L.A. Matsuda","year":"1990","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ, et al.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561\u2013564.","journal-title":"Nature"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S. Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61\u201365.","journal-title":"Nature"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0165-6147(00)01482-6","volume":"21","author":"D. Piomelli","year":"2000","unstructured":"Piomelli D, Giuffrida A, Calignano A, Rodr\u00edguez de Fonseca F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000, 21:218\u2013224.","journal-title":"Trends Pharmacol Sci"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","volume":"54","author":"S. Engeli","year":"2005","unstructured":"Engeli S, B\u00f6hnke J, Feldpausch M, et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838\u20132843.","journal-title":"Diabetes"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.2337\/db06-0812","volume":"55","author":"M. Bluher","year":"2006","unstructured":"Bluher M, Engeli S, Kloting N, et al.: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053\u20133060.","journal-title":"Diabetes"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1172\/JCI17725","volume":"112","author":"D. Cota","year":"2003","unstructured":"Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:323\u2013326.","journal-title":"J Clin Invest"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","volume":"27","author":"U. Pagotto","year":"2006","unstructured":"Pagotto U, Marsicano G, Cota D, et al.: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27:73\u2013100.","journal-title":"Endocr Rev"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","volume":"284","author":"C. Ravinet Trillou","year":"2003","unstructured":"Ravinet Trillou C, Arnone M, Delgorge C, et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345\u2013R353.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","volume":"8","author":"V. Marzo Di","year":"2005","unstructured":"Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585\u2013589.","journal-title":"Nat Neurosci"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","volume":"63","author":"M. Bensaid","year":"2003","unstructured":"Bensaid M, Gary-Bobo M, Esclangon A, et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908\u2013914.","journal-title":"Mol Pharmacol"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/jama.291.14.1730","volume":"291","author":"T. Pischon","year":"2004","unstructured":"Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730\u20131737.","journal-title":"JAMA"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.ijo.0802847","volume":"29","author":"Y.L. Liu","year":"2005","unstructured":"Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)\/Lep(ob) mice. Int J Obes (Lond) 2005, 29:183\u2013187.","journal-title":"Int J Obes (Lond)"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","volume":"115","author":"D. Osei-Hyiaman","year":"2005","unstructured":"Osei-Hyiaman D, DePetrillo M, Pacher P, et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298\u20131305.","journal-title":"J Clin Invest"},{"key":"11_CR20","unstructured":"FDA Rimonabant Hearing June 13, 2007. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007-4306s1-04-Sanofi-Aventis-Rosenzweig.pfd . Accessed on October 2, 2007."},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"L.F. Gaal Van","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389\u20131397.","journal-title":"Lancet"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"J.P. Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121\u20132134.","journal-title":"N Engl J Med"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"F.X. Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761\u2013775.","journal-title":"JAMA"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"A.J. Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660\u20131672.","journal-title":"Lancet"},{"key":"11_CR25","unstructured":"SERENADE confirms efficacy of rimonabant in diabetes. Available at http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/acomplia\/acomplia.htm . Accessed on August 10, 2007."},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.2165\/00003495-200666160-00006","volume":"66","author":"S. Henness","year":"2006","unstructured":"Henness S, Robinson DM, Lyseng-Williamson KA: Rimonabant. Drugs 2006, 66:2109\u20132119; discussion 2120\u20132121.","journal-title":"Drugs"},{"key":"11_CR27","unstructured":"FDA Rimonabant Hearing, June 13, 2007. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007-4306s1-08-Sanofi-Aventis-backup-slides.pdf . Accessed on August 14, 2007."},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R. Padwal","year":"2003","unstructured":"Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003, 27:1437\u20131446.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"11_CR29","unstructured":"EMEA: Scientific Discussion Accomplia. Scientific Review of Accomplia. Available at http:\/\/www.emea.eu.int\/human-docs\/Humans\/EPAR\/acomplia\/acomplia.htm . Accessed on August 10, 2007."},{"key":"11_CR30","unstructured":"FDA Rimonabant Hearing, June 13, 2007. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007-4306s1-05-Sanofi-Aventis-Chew.pdf . Accessed on August 9, 2007."},{"key":"11_CR31","unstructured":"ZIMULTI (rimonabant) NDA 21-888, Briefing Information for FDA Advisory Committee Meeting. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4306b1-01-sponsor-backgrounder.htm . Accessed on August 30, 2007."},{"key":"11_CR32","unstructured":"Acomplia drug patients at psychiatric risk. Available at http:\/\/www.telegraph.co.uk\/news\/main.jhtml?xml=\/news\/2007\/07\/20\/nweight120.xml . Accessed on August 10, 2007."},{"key":"11_CR33","unstructured":"FDA Rimonabant Hearing, June 13, 2007. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007-4306s1-10-FDA-Egan_files\/frame.htm . Accessed on August 5, 2007."},{"key":"11_CR34","unstructured":"EMEA press release, July 19, 2007. Available at http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/acomplia\/32982607en.pdf . Accessed on August 10, 2007."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-008-0011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0011-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:32Z","timestamp":1559432132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-008-0011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11883-008-0011-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}